Companies which are more than 50% undervalued based on analyst price target.

Analysts Target

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
TXGN	CHF 132.40	1.7%	-43.3%	CHF 1.4b	CHF 200.50	158.2	37.9%	3.0%	Media
LAND New	CHF 41.60	-2.9%	-32.1%	CHF 1.2b	CHF 62.48	37.7	32.8%	2.9%	Tech
INRN	CHF 1,298.00	-1.1%	-37.7%	CHF 1.1b	CHF 2,257.14	19.4	10.9%	2.5%	Capital Goods
COPN	CHF 65.20	-4.3%	4.5%	CHF 1.1b	CHF 129.40	11.0	42.0%	3.0%	Pharmaceuticals & Biotech
NEAG	CHF 31.40	-0.6%	4.7%	CHF 1.0b	CHF 60.00	6.0	-22.4%	2.9%	Utilities
KURN	CHF 21.38	12.5%	-23.3%	CHF 843.6m	CHF 34.27	424.6	58.4%	n/a	Pharmaceuticals & Biotech
BSLN	CHF 55.00	3.6%	14.0%	CHF 681.8m	CHF 89.90	16.9	7.8%	n/a	Pharmaceuticals & Biotech
VETN	CHF 18.30	-0.5%	-43.6%	CHF 362.8m	CHF 28.50	95.5	85.4%	2.7%	Materials
CPHN	CHF 56.60	0%	-25.3%	CHF 339.3m	CHF 89.73	14.5	11.7%	3.5%	Materials
MEDX	CHF 8.03	1.1%	-38.2%	CHF 326.6m	CHF 15.80	51.0	37.9%	1.2%	Healthcare
MIKN	CHF 16.50	-1.5%	1.1%	CHF 275.3m	CHF 29.80	8.5	-9.6%	3.6%	Capital Goods
NWRN	CHF 12.04	-5.6%	72.0%	CHF 250.5m	CHF 47.48	14.2	50.2%	n/a	Pharmaceuticals & Biotech
PEAN	CHF 4.33	-0.1%	-28.6%	CHF 240.6m	CHF 7.87	1.8	104.4%	0%	Real Estate Management and Development
SANN	CHF 15.74	3.6%	28.8%	CHF 235.7m	CHF 27.50	3.1	18.6%	n/a	Pharmaceuticals & Biotech
BIOV	CHF 27.60	2.2%	-21.6%	CHF 161.6m	CHF 58.26	50.9	-14.3%	n/a	Pharmaceuticals & Biotech
VARN	CHF 13.45	-2.2%	-32.4%	CHF 136.2m	CHF 25.18	1.5	7.0%	0%	Real Estate Management and Development
MOLN	CHF 3.21	0.3%	9.7%	CHF 120.4m	CHF 9.00	1.8	17.4%	n/a	Pharmaceuticals & Biotech
XLS	CHF 18.00	0%	-8.4%	CHF 102.6m	CHF 50.00	372.8	2.6%	n/a	Pharmaceuticals & Biotech
MMTX	CHF 0.18	-10.0%	n/a	CHF 27.5m	CHF 2.73	42.8	87.7%	n/a	Pharmaceuticals & Biotech
ASWN	CHF 0.59	-6.3%	-45.4%	CHF 8.5m	CHF 2.00	0.4	74.2%	n/a	Media

Top Stock Picks from Analysts